HCA Healthcare Inc. (HCA) Sinks 7.23% After Earnings, EPS Tops Expectations and Beats Revenue

2026-04-24 · Stocks · QuoteReporter

Post Earning Analysis

HCA Healthcare Inc. (HCA) Sinks 7.23% After Earnings, EPS Tops Expectations and Beats Revenue

HCA Healthcare, Inc., founded by Dr. Thomas F. Frist, Jr. in 1968 and headquartered in Nashville, Tennessee, is a leading provider of healthcare services. The company operates a broad network of facilities including hospitals, surgery centers, urgent care clinics, and diagnostic centers. It offers a wide range of medical and surgical services from inpatient and intensive care to outpatient surgery and home health services.

The current price of $436.51 reflects a significant drop of 7.23% today, indicating a bearish movement in the market. This is further reinforced by the price being below all key moving averages (20-day, 50-day, 200-day), with declines of 9.32%, 13.81%, and 4.01% respectively, suggesting a negative trend over short and medium terms.

The stock is currently 21.45% below its 52-week and YTD highs of $555.69, yet it remains 36.73% above its 52-week low and 51.89% above the YTD low, indicating considerable volatility over the past year. Recent performance shows the price near its weekly low of $422.23, but still above it, which might offer a slight support level.

The RSI at 26.12 suggests the stock is in an oversold condition, which could potentially signal a buying opportunity if other conditions align. However, the MACD at -10.37 supports the bearish trend, indicating that the downward momentum is strong. Overall, the indicators suggest caution, as the current bearish trend may continue unless there is a significant positive shift in market sentiment or company fundamentals.

Earnings Trend Table

Analyzing the EPS trends from the data provided, there is a clear pattern of fluctuation in both the estimated and reported EPS over the quarters spanning from October 2023 to April 2026. Initially, in October 2023, the reported EPS slightly underperformed against the estimate, marking a -1.85% surprise. However, a significant improvement is observed in subsequent quarters. From January 2024 through April 2024, there was a notable increase in reported EPS, consistently outperforming estimates with surprises ranging from 17.15% to 18.46%.

A temporary dip occurred in January 2025, where the reported EPS fell below the estimate by -8.02%, indicating a quarter of underperformance. This was quickly corrected in the following quarters, with April 2025 showing a substantial positive surprise of 11.62%, and a modest beat in April 2026 with a 0.42% surprise.

This trend suggests a generally strong performance relative to expectations, with occasional volatility. The data highlights the company’s ability to exceed analyst expectations significantly in most quarters, despite periodic setbacks. Such patterns are crucial for understanding the company's financial health and operational efficiency over time.

Dividend Payments Table

The dividend data over the observed periods indicates a progressive upward trend in dividend payouts. Commencing in June 2024, dividends were consistently distributed at $0.66 per share for three consecutive quarters. This stability suggests a phase of financial steadiness or a conservative payout strategy by the entity in question during that fiscal year.

Subsequently, there was a notable increase to $0.72 per share starting from December 2024, which persisted through four quarters until March 2025. This increment reflects a positive adjustment in the dividend policy, potentially indicative of improved profitability or a more confident financial outlook by the company's management.

The most recent data point from March 2026 shows a further increase in the dividend to $0.78. This continued upward adjustment not only underscores a sustained positive financial performance but also highlights a commitment to enhancing shareholder value over time. Overall, the trend across these periods suggests a healthy financial trajectory and a robust dividend policy.

The most recent rating changes present a nuanced view of the financial market's perception of the concerned entity, with significant adjustments made by notable firms.

1. Morgan Stanley on December 15, 2025: This firm downgraded its rating from Equal-Weight to Underweight, setting a new target price at $425. This change indicates a bearish outlook, suggesting that Morgan Stanley analysts foresee underperformance relative to the broader market or sector.

2. Goldman on October 14, 2025: The resumption of coverage by Goldman with a Buy rating and a target price of $470 contrasts with other recent analyst sentiments. This indicates a bullish perspective from Goldman, implying expected outperformance and a potential undervaluation at previous levels.

3. Wolfe Research on July 28, 2025: The downgrade from Outperform to Peer Perform, without a specific target price, suggests a neutral stance. Wolfe Research likely sees the entity performing in line with its peers, rather than continuing to outperform.

4. BofA Securities on July 16, 2025: This firm downgraded its rating from Buy to Neutral, setting the target price at $394. This adjustment points to a shift from a bullish to a more cautious outlook, indicating expectations of average market performance, possibly due to emerging risks or lack of new growth catalysts.

These shifts in ratings and target prices reflect a mixed consensus among analysts, suggesting varying expectations about the entity's future performance and market conditions.

The current price of the stock is $436.51. This figure is positioned between the divergent target prices provided by major financial institutions. Notably, Goldman Sachs has a more optimistic outlook with a target price of $470, suggesting a potential upside. Conversely, Morgan Stanley and BofA Securities provide more conservative estimates at $425 and $394, respectively, both below the current stock price. This discrepancy indicates a mixed sentiment among analysts regarding the stock's future performance, with recent downgrades from Morgan Stanley and BofA Securities, and a more bullish perspective from Goldman Sachs.

The diversity in these target prices and ratings reflects varying analyst perspectives and market conditions that potential investors should consider. The recent downgrades could suggest concerns about the company's near-term growth prospects or market conditions, whereas the higher target by Goldman Sachs might indicate confidence in the company's fundamental strength or market strategy.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.